<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526184</url>
  </required_header>
  <id_info>
    <org_study_id>IMU</org_study_id>
    <nct_id>NCT04526184</nct_id>
  </id_info>
  <brief_title>The Effect of Blood Flow Restricted Aerobic Exercise on Chronic Obstructive Pulmonary Patients</brief_title>
  <official_title>The Effect of Blood Flow Restricted Aerobic Exercise on Chronic Obstructive Pulmonary Patients: A Comparative Study With a Healthy Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with COPD that a pulmonologist classifies between Stage 1-4 in accordance with the&#xD;
      GOLD criteria and age and gender-matched healthy individuals will be included in the study.&#xD;
&#xD;
      In both groups (n = COPD: 25, Healthy: 25), aerobic exercise (AE) in the target heart rate&#xD;
      range of 50% intensity, performed by cycling accompanied by blood flow restriction, will be&#xD;
      applied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Target heart rate will be calculated from the formula &quot;(Maximal heart rate-resting heart&#xD;
      rate) x% desired intensity ratio + resting heart rate&quot;.&#xD;
&#xD;
      The target occlusion amount in the lower extremity will be calculated by calculating 45% of&#xD;
      the complete occlusion rates reported by Michael et al. The proximal border of the thigh&#xD;
      cuffs will be tied in line with the gluteal lines on both sides.&#xD;
&#xD;
      Exercise tolerance and dyspnea condition; Measurement properties in COPD will be evaluated&#xD;
      using a well-defined modified Borg scale (MBS). Individuals will use any bronchodilator that&#xD;
      their doctor sees fit before trying.&#xD;
&#xD;
      The target aerobic exercise intensity will be reached in the last minute of the first&#xD;
      five-minute warm-up period by maintaining a 4-6 feeling of dyspnea in the MBS, by increasing&#xD;
      pedal resistance and speed. In case of extreme shortness of breath, exercise intensity will&#xD;
      be reduced to resting heart rate.&#xD;
&#xD;
      In the event of oxygen desaturation (85%) during the intervention, the intervention will be&#xD;
      terminated.&#xD;
&#xD;
      Aerobic exercise training protocol; It was planned as 50 rpm speed and warming up at the&#xD;
      lowest pedal resistance during the first 4 minutes, reaching the target exercise intensity&#xD;
      range in the next 1 minute, aerobic training at the target heart rate range and appropriate&#xD;
      MBS value for the next 20 minutes, cooling down in the last 5 minutes. The duration will be&#xD;
      reduced in case of excessive shortness of breath, fatigue and muscle pain due to increased&#xD;
      exercise volume. The distance, calories, and maximum speed values measured during the study&#xD;
      will be recorded.&#xD;
&#xD;
      Before and immediately after the study, all participants had rhabdomyolysis status (creatine&#xD;
      kinase), risk of venous thromboembolism (D-dimer, CRP), anti-inflammatory response (IL-6),&#xD;
      oxygen saturation, heart rate, systolic and diastolic pressure, respiratory rate, six-minute&#xD;
      walking test parameters will be examined.&#xD;
&#xD;
      Institution of the Study: Karabuk University Research Hospital Chest Diseases Clinic Center /&#xD;
      Karabuk. The study would be conducted in the presence of a chest diseases specialist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">December 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups will be formed as healthy and patient groups and the same treatment initiative will be applied.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Groups will be formed randomly from 103 COPD patients and healthy individuals contacted by phone.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>creatine kinase</measure>
    <time_frame>30 minutes</time_frame>
    <description>rhabdomyolysis marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>D-dimer</measure>
    <time_frame>30 minutes</time_frame>
    <description>venous thromboembolism marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>30 minutes</time_frame>
    <description>clot formation marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxygen saturation</measure>
    <time_frame>30 minutes</time_frame>
    <description>blood oxygen stauration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>30 minutes</time_frame>
    <description>determination of aerobic exercise dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic and diastolic pressure</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>aerobic exercise tolerance measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified borg scale</measure>
    <time_frame>up to 18 weeks.</time_frame>
    <description>dyspnoea measurement, Minimum 0, maximum 10 points are obtained. 0 indicates the best respiratory condition, 10 the worst respiratory condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minutes walk test</measure>
    <time_frame>40 minutes</time_frame>
    <description>strength measurement</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>healthy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 healthy individuals between the ages of 40-70 will be contacted by phone and included in the initiative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patient group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 individuals will be selected randomly from 103 patients with COPD from hospital records.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>aerobic exercise with blood flow restriction</intervention_name>
    <description>Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.</description>
    <arm_group_label>healthy group</arm_group_label>
    <arm_group_label>patient group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No drug change for at least 30 days for the COPD group&#xD;
&#xD;
          -  Not participating in a structured activity program for at least six months&#xD;
&#xD;
          -  Have the ability to cooperate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any pathology that limits physical activity performance&#xD;
&#xD;
          -  Presence of severe or unstable heart disease&#xD;
&#xD;
          -  Presence of peripheral artery disease&#xD;
&#xD;
          -  Being in an exacerbation period of the disease&#xD;
&#xD;
          -  Presence of another active disease (rheumatic, oncological, traumatic etc.)&#xD;
&#xD;
          -  Any neurological or orthopedic disease that prevents exercise&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Because COPD is generally more common in males, patients of this gender were included in the study.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karabük Üniversitesi Araştırma Hastanesi Göğüs Hastalıkları Kliniği</name>
      <address>
        <city>Karabük</city>
        <zip>78600</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, Abe T, Nielsen JL, Libardi CA, Laurentino G, Neto GR, Brandner C, Martin-Hernandez J, Loenneke J. Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. Front Physiol. 2019 May 15;10:533. doi: 10.3389/fphys.2019.00533. eCollection 2019. Review. Erratum in: Front Physiol. 2019 Oct 22;10:1332.</citation>
    <PMID>31156448</PMID>
  </results_reference>
  <results_reference>
    <citation>Kacin A, Strazar K. Frequent low-load ischemic resistance exercise to failure enhances muscle oxygen delivery and endurance capacity. Scand J Med Sci Sports. 2011 Dec;21(6):e231-41. doi: 10.1111/j.1600-0838.2010.01260.x. Epub 2011 Mar 8.</citation>
    <PMID>21385216</PMID>
  </results_reference>
  <results_reference>
    <citation>Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. Sports Med. 2015 Mar;45(3):313-25. doi: 10.1007/s40279-014-0288-1. Review.</citation>
    <PMID>25430600</PMID>
  </results_reference>
  <results_reference>
    <citation>Nolan CM, Rochester CL. Exercise Training Modalities for People with Chronic Obstructive Pulmonary Disease. COPD. 2019 Dec;16(5-6):378-389. doi: 10.1080/15412555.2019.1637834. Epub 2019 Nov 4. Review.</citation>
    <PMID>31684769</PMID>
  </results_reference>
  <results_reference>
    <citation>Loenneke JP, Allen KM, Mouser JG, Thiebaud RS, Kim D, Abe T, Bemben MG. Blood flow restriction in the upper and lower limbs is predicted by limb circumference and systolic blood pressure. Eur J Appl Physiol. 2015 Feb;115(2):397-405. doi: 10.1007/s00421-014-3030-7. Epub 2014 Oct 22.</citation>
    <PMID>25338316</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson JM, Lowery RP, Joy JM, Loenneke JP, Naimo MA. Practical blood flow restriction training increases acute determinants of hypertrophy without increasing indices of muscle damage. J Strength Cond Res. 2013 Nov;27(11):3068-75. doi: 10.1519/JSC.0b013e31828a1ffa.</citation>
    <PMID>23446173</PMID>
  </results_reference>
  <results_reference>
    <citation>Berzosa C, Cebrián I, Fuentes-Broto L, Gómez-Trullén E, Piedrafita E, Martínez-Ballarín E, López-Pingarrón L, Reiter RJ, García JJ. Acute exercise increases plasma total antioxidant status and antioxidant enzyme activities in untrained men. J Biomed Biotechnol. 2011;2011:540458. doi: 10.1155/2011/540458. Epub 2011 Mar 9.</citation>
    <PMID>21436993</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>December 27, 2020</last_update_submitted>
  <last_update_submitted_qc>December 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medipol University</investigator_affiliation>
    <investigator_full_name>Ahmet Gunes</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

